Skip to main contentSkip to navigationSkip to search

Denmark-based biotech Curasight making strides in cancer therapies

CSO and Co-Founder of Curasight Andreas Kjaer spoke with Informa Pharma Intelligence at BioPharm America about his company’s efforts to develop novel, innovative radionuclide therapies for cancer. With two completed Phase I trials and an ongoing Phase II study with its lead candidate in breast cancer, this Denmark-headquartered biotech also is developing companion diagnostic PET imaging ligands to improve diagnosis, treatment and outcomes in cancer. Krasilnikoff also talked about Curasight’s efforts to raise its profile in North America, including potential partnering talks at BioPharm America in Boston. 

Latest Press Releases

Results from Phase II study in prostate cancer to be published in the Journal of Nuclear Medicine

December 21, 2020
 | Regulatory

Japanese patent application 2019-005811 is accepted for grant

December 16, 2020
 | Regulatory

Financial Calendar 2021

December 15, 2020
 | Regulatory